Lung cancer combo trial halted after just 4 patients

NCT ID NCT05215951

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meaningful conclusions can be drawn. The goal was to see if the combination could shrink tumors and delay cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: osimertinib (Tagrisso) plus platinum and pemetrexed chemotherapy
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has rare EGFR mutations.
What could go wrong: This was a very small, early-phase study that was terminated early, so results are limited. The combination may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Research Site

Chengdu, 610041, China
Research Site

Harbin, 150049, China
Research Site

Mianyang, 621000, China
Research Site

Nanchong, 637000, China
Research Site

Yibin, 644000, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.